Santhera Withdraws Raxone MAA, Plans Resubmission
With additional data in the offing for its Leber's hereditary optic neuropathy drug Raxone, Santhera Pharmaceuticals AG has withdrawn its marketing authorization application from the European Medicines Agency's re-examination process and will instead submit a new file with an expanded patient database.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter